Table 1.
Baseline population characteristics
| Parameters | Chronic HBV infection | |||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 291) | HBeAg positive | HBeAg negative | P# value | |||||
| Total (n = 156) | Immune tolerant, IT (n = 35) | HBeAg positive immune active hepatitis, EPIA (n = 121) | Total (n = 135) | Inactive chronic hepatitis B, ICH (n = 77) | HBeAg negative reactive hepatitis, ENH (n = 58) | |||
| Age, years median(IQR) |
37(30,46) | 33(28,41) | 30(27.5,34.0) | 34.0 (28.0,42.0) | 41(33,52) | 40.0 (31.0,50.0) | 42.0(35.0,53.0) | 0.000 |
| Gender, M/F | 206/85 | 114/42 | 25/10 | 89/32 | 92/43 | 45/32 | 47/11 | 0.028 |
| Disease category(CH/LC/HCC) | 240/51/0 | 125/31/0 | 30/0/0 | 90/31/0 | 115/20/0 | 74/3/0 | 41/17/0 | / |
| Child-Pugh class(A/B/C) | 31/11/9 | 23/4/4 | na | 23/4/4 | 8/7/5 | 1/1/1 | 7/6/4 | / |
| HBsAg, log IU/mL, median(IQR) | 3.49(2.91,4.12) | 3.92(3.27,4.56) | 4.56(4.13,4.71) | 3.71(3.22,4.31) | 2.98(2.38,3.58) | 2.94(2.32,3.54) | 3.00(2.48,3.66) | 0.000 |
| HBeAg, log S/CO median(IQR) | na | 2.81(1.67,3.11) | 3.01(3.07,3.17) | 2.58(1.46,3.03) | na | na | na | 0.005 |
| HBV DNA,log copies/mL, median(IQR) | 5.94(3.63,8.14) | 7.65(5.87,8.43) | 8.44(8.15,8.43) | 7.11(5.39,8.44) | 3.61(2.74,5.20) | 2.74(2.74,3.82) | 5.48(4.09,6.65) | 0.000 |
| HBV RNA,log copies/mL median(IQR) |
5.50(2.57,7.16) | 6.82(5.57,7.98) | 7.87(6.08,8.30) | 6.67(5.433,7.80) | 2.40(2.00,5.23) | 2.00(2.00,3.04) | 5.31(3.57,6.37) | 0.000 |
| ALT,IU/L median(IQR) | 59(30,191) | 88.5(42.5261.0) | 34(28.5,43.5) | 153(66.50,348.50) | 36(20,100.50) | 24(18,34) | 131(67,309) | 0.000 |
| AST,IU/L median(IQR) | 41(23,102) | 58.5(31,116) | 27(23,31.5) | 76.5(44,157) | 27(21,56) | 21(19,26) | 89.5(39,188) | 0.000 |
IQR interquantile range, HBeAg Hepatitis B e antigen, CH chronic hepatitis, LC liver cirrhosis, na not applicable, HCC hepatocellular carcinoma, HBsAg Hepatitis B surface antigen, HBV hepatitis B virus, AST aspartate aminotransferase, ALT alanine aminotransferase. P# value: compared between patients with HBeAg-positive and patients with HBeAg-negative